102766-74-5 Usage
Uses
Used in Pharmaceutical Industry:
2-METHYL-4-(4-TRIFLUOROMETHYL-PHENOXY)-PHENYLAMINE is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs due to its unique chemical structure and properties.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 2-METHYL-4-(4-TRIFLUOROMETHYL-PHENOXY)-PHENYLAMINE serves as a key component in the synthesis of agrochemicals, potentially leading to the creation of novel products for agricultural applications.
Used in Research and Development:
2-METHYL-4-(4-TRIFLUOROMETHYL-PHENOXY)-PHENYLAMINE is utilized in research and development settings to explore its unique molecular structure and properties, which may lead to advancements in chemical and material sciences.
Check Digit Verification of cas no
The CAS Registry Mumber 102766-74-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,2,7,6 and 6 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 102766-74:
(8*1)+(7*0)+(6*2)+(5*7)+(4*6)+(3*6)+(2*7)+(1*4)=115
115 % 10 = 5
So 102766-74-5 is a valid CAS Registry Number.
InChI:InChI=1/C14H12F3NO/c1-9-8-12(6-7-13(9)18)19-11-4-2-10(3-5-11)14(15,16)17/h2-8H,18H2,1H3
102766-74-5Relevant academic research and scientific papers
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis
Akama, Tsutomu,Baker, Stephen J.,Zhang, Yong-Kang,Hernandez, Vincent,Zhou, Huchen,Sanders, Virginia,Freund, Yvonne,Kimura, Richard,Maples, Kirk R.,Plattner, Jacob J.
scheme or table, p. 2129 - 2132 (2009/12/07)
A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.
